Indications
- Bleeding in Presence of Hyperfibrinolysis (see Hyperfibrinolytic States, [[Hyperfibrinolytic States]])
- Plasminogen Activator Inhibitor-1 (PAI-1) Deficiency (see Plasminogen Activator Inhibitor-1 Deficiency, [[Plasminogen Activator Inhibitor-1 Deficiency]])
- Von Willebrand Disease (see Von Willebrand Disease, [[Von Willebrand Disease]])
Pharmacology
- Anti-Fibrinolytic (see Anti-Fibrinolytics, [[Anti-Fibrinolytics]]): lysine analogue which binds to kringle domains of plasminogen, disrupting interaction between plasminogen (and plasmin) and lysine residues within fibrin
- Tranexamic Acid (see Tranexamic Acid, [[Tranexamic Acid]]): binds plasminogen (and plasmin) 8x more avidly than the older epsilon aminocaproic acid analogue -> may exert a more potent anti-hemorrhagic effect
Administration
- IV
Adverse Effects
Other Adverse Effects
- xxx
- xxx
- xxx
References
- xxxx
s